Get notified when KZIA files again. Create a free account and we'll email you the moment its next filing is analyzed.
Get filing alertsRed Flags Detected
- Going Concern (new) — The auditor's report includes a going concern explanatory paragraph, indicating substantial doubt about Kazia's ability to continue operating.
Kazia Therapeutics prices $37M net ADS and warrants offering at $15.50 per ADS
Filed August 31, 2026 · ~1 min read
Key Changes
-
high
Kazia is selling 2,276,800 ADSs at $15.50 each plus warrants, expecting about $37 million in net proceeds.
The Offering verify on EDGAR → -
high
The company may receive up to an additional $80 million if Series A and Series B warrants are fully exercised.
Use of Proceeds verify on EDGAR → -
high
Net proceeds will fund paxalisib clinical development in TNBC, HR+/HER2- breast cancer, and colorectal cancer.
Use of Proceeds verify on EDGAR →
2 more material changes behind this preview — plus the full narrative summary, section-by-section diffs against the prior filing, and verbatim quotes with EDGAR citations.
Want to see a complete report first? Today's free report (ESTC 10-Q) is open in full — no account needed.
Partner
Trade KZIA commission-free
Open an account, get a free stock.
Investing involves risk. Free stock terms apply.
Thanks — your feedback helps us improve report quality.
Figures/quotes linked to EDGAR · Narrative written by AI · Aug 31, 2026 · How we verify